Application of Longistyline A-2-carboxylic acid in osteoclast formation inhibiting and osteoporosis preventing medicines

A technology for osteoporosis and osteoclast inhibition, which can be used in drug combinations, bone diseases, pharmaceutical formulations, etc., and can solve problems such as unclear osteoporosis

Inactive Publication Date: 2018-01-26
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since lignanin has been used in anti-inflammatory, anti-bacterial, anti-oxidative, anti-apoptoti...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Longistyline A-2-carboxylic acid in osteoclast formation inhibiting and osteoporosis preventing medicines
  • Application of Longistyline A-2-carboxylic acid in osteoclast formation inhibiting and osteoporosis preventing medicines
  • Application of Longistyline A-2-carboxylic acid in osteoclast formation inhibiting and osteoporosis preventing medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] The specific embodiment of the present invention is described further below, and for convenience of description, the raw material and material that the present invention adopts have explained purchase factory respectively, but do not therefore limit the scope of the present invention.

[0028] 1 method

[0029] 1.1 Materials and reagents

[0030] Phylogenin was purchased from Chengdu Master Biotechnology Co., Ltd. (Chengdu, Sichuan Province, China) and dissolved in phosphate solution (PBS). α-MEM medium and fetal bovine serum (FBS) were purchased from TRACE (Sydney, Australia). Anti-P-ERK, anti-IκBα and anti-β-actin antibodies were purchased from Santa Cruz Biotechnology (California, USA), anti-NFATc1 antibodies were purchased from BD Bioscience (USA), C-Fos and V-ATPase-d2 antibodies were purchased from BD Biological Sciences (USA). Luciferase, reactive oxygen species response (ROS) and MTS assay kits were purchased from Promega (Sydney, Australia).

[0031] 1.2 In...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of Longistyline A-2-carboxylic acid in osteoclast formation inhibiting and osteoporosis preventing medicines. The chemical structural formula of the LongistylineA-2-carboxylic acid is shown in the description. The invention also provides an application of the Longistyline A-2-carboxylic acid in medicines for inhibiting the osteoclast marker gene expression in the osteoclast formation process, an application of the Longistyline A-2-carboxylic acid in medicines for inhibiting the RANKL-induced NF-kappa and NFAT pathway activity through inhibiting the expression level of proteins in the upstream and downstream pathways in the osteoclast differentiation process, and an application of the Longistyline A-2-carboxylic acid in medicines for inhibiting RANKL-induced reactive oxygen species (ROS) and important calcium ion oscillation reactions in the osteoclast differentiation process. RANKL-induced osteoclast formation and the functions of osteoclast areinhibited to reduce the bone loss in OVX mice; and the Longistyline A-2-carboxylic acid can improve the bone mineral density of OP patients, which proves that the Longistyline A-2-carboxylic acid canbe a potential choice for treating osteoporosis and other osteolytic diseases.

Description

technical field [0001] The present invention relates to a kind of lignan and its application, in particular to the application of a kind of lignan in inhibiting the formation of osteoclasts and preventing osteoporosis. Background technique [0002] Bone is a dynamic tissue in the human body that maintains its structural stability through continuous bone remodeling and mineralization. Bone tissue includes osteoblasts, osteoclasts, and osteocytes. The bone formation ability of osteoblasts and the bone resorption function of osteoclasts play an important role in maintaining the balance of bone remodeling. The dysfunction of osteoclast bone resorption and osteoblast bone formation will lead to bone diseases such as osteoporosis. Osteoporosis is characterized by decreased bone density, microarchitectural destruction of bone tissue leading to decreased bone strength, increased bone fragility, and increased fracture risk. According to a report by the WHO, approximately 72% of wo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P19/10
Inventor 何伟陈雷雷孙友强王海彬刘予豪张庆文徐家科
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap